文献速递多重用药

加拿大老年人潜在不适当用药的成本:一项比较性横断面研究

The cost of potentially inappropriate medications for older adults in Canada: A comparative cross-sectional study.
PubMed 文献 · J Am Geriatr Soc · 2024-09-05

该横断面研究基于加拿大国家处方药利用信息系统2021年与2013年的索赔数据,采用改编自美国老年医学会的标准,分析65岁及以上老年人潜在不适当用药(PIM)的直接成本。但加巴喷丁类、质子泵抑制剂和抗精神病药暴露增加,每季度暴露率下降16.4%。

要点

  • 2021年加拿大老年人PIM总支出10亿加元,较2013年下降33.6%。
  • 加巴喷丁类、质子泵抑制剂和抗精神病药暴露增加,需针对性干预。

核心结论

  • 加拿大PIM支出虽下降但总体仍高,部分严重危害类别处方增加,需定向可扩展干预。

研究设计与样本

  • 横断面研究,使用加拿大国家处方药利用信息系统2021年与2013年65岁及以上人群处方索赔数据,采用改编自美国老年医学会的PIM标准。

主要发现

  • 每暴露者季度PIM支出从95加元降至57加元。
  • 阿片类和抗精神病药每暴露者平均成本最高(138加元和118加元)。
  • PIM季度暴露率下降16.4%(从2013年每万人7301降至2021年每万人6106)。

关键数值与推荐

  • PIM标准改编自美国老年医学会。
  • 每暴露者季度支出从95加元降至57加元。
  • PIM季度暴露率从每万人7301降至每万人6106。

临床怎么用

  • 关注加巴喷丁类、质子泵抑制剂和抗精神病药等暴露增加的PIM类别。
  • 针对高成本PIM类别(如阿片类、抗精神病药)实施定向处方优化干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Potentially inappropriate medications (PIMs) are medications whereby the harms may outweigh the benefits for a given individual. Although overprescribed to older adults, their direct costs on the healthcare system are poorly described. METHODS: This was a cross-sectional study of the cost of PIMs for Canadians aged 65 and older, using adapted criteria from the American Geriatrics Society. We examined prescription claims information from the National Prescription Drug Utilization Information System in 2021 and compared these with 2013. The overall levels of inflation-adjusted total annual expenditure on PIMs, average cost per quarterly exposure, and average quarterly exposures to PIMs were calculated in CAD$. RESULTS: Exposure to most categories of PIMs decreased, aside from gabapentinoids, proton pump inhibitors, and antipsychotics, all of which increased. Canadians spent $1 billion on PIMs in 2021, a 33.6% reduction compared with 2013 ($1.5 billion). In 2021, the largest annual expenditures were on proton pump inhibitors ($211 million) and gabapentinoids ($126 million). The quarterly amount spent on PIMs per person exposed decreased from $95 to $57. In terms of mean cost per person, opioids and antipsychotics were highest ($138 and $118 per exposure). Some cost savings may have occurred secondary to an observed decline of 16.4% in the quarterly rate of exposure to PIMs (from 7301 per 10,000 in 2013 to 6106 per 10,000 in 2021). CONCLUSIONS: While expenditures on PIMs have declined in Canada, the overall cost remains high. Prescribing of some seriously harmful classes of PIMs has increased and so directed, scalable interventions are needed.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Huon JF, Sanyal C, Gagnon CL, et al. The cost of potentially inappropriate medications for older adults in Canada: A comparative cross-sectional study. J Am Geriatr Soc. 2024. PMID: 39235969. doi:10.1111/jgs.19164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。